| 1.805 -0.015 (-0.82%) | 05-27 14:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.22  |
1-year : | 2.49 |
| Resists | First : | 1.9 |
Second : | 2.14 |
| Pivot price | 1.77 |
|||
| Supports | First : | 1.52 | Second : | 1.27 |
| MAs | MA(5) : | 1.75  |
MA(20) : | 1.79 |
| MA(100) : | 2.05 |
MA(250) : | 2.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.8 |
D(3) : | 57 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 4.34 | Low : | 1.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GANX ] has closed below upper band by 43.2%. Bollinger Bands are 61.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.95 - 1.96 | 1.96 - 1.96 |
| Low: | 1.78 - 1.79 | 1.79 - 1.8 |
| Close: | 1.81 - 1.82 | 1.82 - 1.83 |
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Tue, 26 May 2026
Gain Therapeutics presents phase 1b data on Parkinson’s drug - Investing.com UK
Tue, 26 May 2026
GT-02287 shows biomarker, symptom stability in Gain (GANX) Parkinson’s study - Stock Titan
Tue, 26 May 2026
Parkinson’s patients report better smell, sleep, balance on experimental GT-02287 - Stock Titan
Tue, 26 May 2026
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - Yahoo Finance
Mon, 11 May 2026
Gain Parkinson’s trial sees 81% biomarker drop, Phase 2 planned - Stock Titan
Mon, 11 May 2026
Gain Therapeutics (NASDAQ: GANX) posts higher Q1 2026 loss and flags going concern risk - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 19.2 (%) |
| Shares Short | 3,440 (K) |
| Shares Short P.Month | 3,280 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.2 % |
| Return on Equity (ttm) | -214.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.24 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -3.1 |
| PEG Ratio | 0 |
| Price to Book value | 5.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|